Comparison of the IKr blockers moxifloxacin, dofetilide and E‐4031 in five screening models of pro‐arrhythmia reveals lack of specificity of isolated cardiomyocytes

Drug development requires the testing of new chemical entities for adverse effects. For cardiac safety screening, improved assays are urgently needed. Isolated adult cardiomyocytes (CM) and human embryonic stem cell‐derived cardiomyocytes (hESC‐CM) could be used to identify pro‐arrhythmic compounds. In the present study, five assays were employed to investigate their sensitivity and specificity for evaluating the pro‐arrhythmic properties of IKr blockers, using moxifloxacin (safe compound) and dofetilide or E‐4031 (unsafe compounds).

[1]  M. Vos,et al.  Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.

[2]  M. Vos,et al.  Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. , 2003, Cardiovascular research.

[3]  D. Rosenbaum,et al.  Role of Structural Barriers in the Mechanism of Alternans-Induced Reentry , 2000, Circulation research.

[4]  G. Faich,et al.  Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections , 2004, The Annals of Pharmacotherapy.

[5]  D. Bloomfield,et al.  The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Step 5 NOTE FOR GUIDANCE ON THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS (CHMP/ICH/2/04) TRANSMISSION TO CHMP , 2002 .

[6]  M. Hashimoto,et al.  [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals]. , 2003, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[7]  Abrar H. Shah,et al.  Moxifloxacin-induced torsades de pointes. , 2008, Cardiology journal.

[8]  J. Valentin,et al.  A Rabbit Langendorff Heart Proarrhythmia Model: Predictive Value for Clinical Identification of Torsades de Pointes , 2006, British journal of pharmacology.

[9]  M. Zeitlinger,et al.  Plasma protein binding of fluoroquinolones affects antimicrobial activity. , 2008, The Journal of antimicrobial chemotherapy.

[10]  M. Vos,et al.  Literature‐based evaluation of four ‘hard endpoint’ models for assessing drug‐induced torsades de pointes liability , 2008, British journal of pharmacology.

[11]  B. Peng,et al.  Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. , 2010, British journal of clinical pharmacology.

[12]  T. Paul,et al.  Sotalol Associated Torsades de Pointes Tachycardia in a 15‐Month‐Old Child: Successful Therapy with Magnesium Aspartate , 1998, Pacing and clinical electrophysiology : PACE.

[13]  D. Roden,et al.  Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  Leif Carlsson,et al.  Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo , 2009, Journal of cardiovascular pharmacology.

[15]  H. Wellens,et al.  Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. , 2001, European journal of pharmacology.

[16]  Jean-Pierre Valentin,et al.  I(Ks) restricts excessive beat-to-beat variability of repolarization during beta-adrenergic receptor stimulation. , 2010, Journal of molecular and cellular cardiology.

[17]  A. Bruening-Wright,et al.  The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. , 2010, Journal of pharmacological and toxicological methods.

[18]  H. Stass,et al.  Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects , 1998, Antimicrobial Agents and Chemotherapy.

[19]  Borje Darpo,et al.  ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs , 2005 .

[20]  U. Moretti,et al.  Antimicrobials and the Risk of Torsades de Pointes , 2010, Drug safety.

[21]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.

[22]  M. Vos,et al.  No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic‐AV block , 2006, British journal of pharmacology.

[23]  James A Thomson,et al.  Human Embryonic Stem Cells Develop Into Multiple Types of Cardiac Myocytes: Action Potential Characterization , 2003, Circulation research.

[24]  H. Elming,et al.  Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. , 2007, The American journal of cardiology.

[25]  Antonio Zaza,et al.  Reverse rate dependency is an intrinsic property of canine cardiac preparations. , 2009, Cardiovascular research.

[26]  M. Vos,et al.  Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. , 2007, Cardiovascular research.

[27]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[28]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[29]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[30]  J. Papp,et al.  Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve , 2002, British journal of pharmacology.

[31]  J. Valentin,et al.  Dog left ventricular midmyocardial myocytes for assessment of drug‐induced delayed repolarization: short‐term variability and proarrhythmic potential , 2010, British journal of pharmacology.

[32]  F. Younas,et al.  Moxifloxacin-Induced QT Prolongation and Torsades: An Uncommon Effect of a Common Drug , 2009, The American journal of the medical sciences.

[33]  Jules C Hancox,et al.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin , 2006, British journal of pharmacology.

[34]  Lior Gepstein,et al.  In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.

[35]  L. Carlsson,et al.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.

[36]  D. Roden.  Mechanisms and management of proarrhythmia. , 1998, The American journal of cardiology.

[37]  L. Carlsson.  The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. , 2008, Pharmacology & therapeutics.

[38]  B F Hoffman,et al.  Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.

[39]  M. Vos,et al.  Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. , 2010, Journal of the American College of Cardiology.

[40]  S. Choudhri,et al.  Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials , 2005, Drug safety.

[41]  K. Hashimoto,et al.  In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. , 2004, European journal of pharmacology.

[42]  Katriina Aalto-Setälä,et al.  Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype , 2010, Experimental biology and medicine.

[43]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[44]  N. Sarapa,et al.  Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc Studies , 2008, Clinical pharmacology and therapeutics.

[45]  M. Vos,et al.  The canine model with chronic, complete atrio-ventricular block. , 2008, Pharmacology & therapeutics.

[46]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[47]  Abrar H. Shah,et al.  Moxifloxacin-induced torsade de pointes , 2008 .

[48]  E. Kadyszewski,et al.  QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome , 2005, British journal of pharmacology.

[49]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[50]  L. Carlsson,et al.  QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions , 1990, Journal of cardiovascular pharmacology.

[51]  A. Sugiyama,et al.  Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. , 2008, European journal of pharmacology.

[52]  R S Reneman,et al.  An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.

[53]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[54]  Martin Hinterseer,et al.  Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. , 2007, European heart journal.

[55]  B. Olsson,et al.  Molecular Signature of Cardiomyocyte Clusters Derived from Human Embryonic Stem Cells , 2008, Stem cells.